Table 6. Stratified D210 efficacy.
| AmBisome + SSG | AmBisome + Miltefosine | Miltefosine | ||
|---|---|---|---|---|
| Country | Sudan | 21/24 (88%) | 17/24 (71%) | 18/27 (67%) |
| Kenya | 26/27 (96%) | 23/25 (92%) | 20/24 (83%) | |
| Fisher’s exact test p-value (2-sided) | 0.331 | 0.074 | 0.211 | |
| Age | Less than 12 years | 22/25 (88%) | 20/27 (74%) | 13/22 (59%) |
| 12 years and above | 25/26 (96%) | 20/22 (90%) | 25/29 (86%) | |
| Fisher’s exact test p-value (2-sided) | 0.350 | 0.159 | 0.050 | |
| Sudan | Less than 12 years | 12/15 (80%) | 13/19 (68%) | 9/15 (60%) |
| 12 years and above | 9/9 (100%) | 4/5 (80%) | 9/12 (75%) | |
| Kenya | Less than 12 years | 10/10 (100%) | 7/8 (88%) | 4/7 (57%) |
| 12 years and above | 16/17 (94%) | 16/17 (94%) | 16/17 (94%) | |
Data are number cured / number randomised (%). As estimates of cure rates, these percentages do not take into account the sequential design.